Mother to child transmission remains a major means of HIV
transmission. HIv can be transmitted from the mother to the child
through 3 routes:

1. During pregnancy when the mother goes through trauma that may
cause a tear in the placenta and allow direct contact between the
mother and the child’s blood. This should not happen normally. This
route of transmission for HIV infection from mother to child is quite
low

2. At delivery. When delivery is not taken carefully and the child is
exposed to contact with the mother’s vaginal fluid which is infected
with the virus, or the mother’s blood.ideally, HIV infected pregant
mothers should be slated for caserean section so as to further reduce this possibility

3. After birth through breast milk. This is the most common route of
infection. The breastmilk contains HIV virus. the virus could infect
the child through the gut. the gut contains a lot of CD4 cells and
therefore HIV infection can easily occur in the gut when exposed to
the virus. Often times, HIV infected mothers are advised not to
breastfeed. When they opt too for a number of different reasons, they are advised to breastfeed exclusively (breastfeed the child strictly on breastmilk only) before weaning off the child. Exclusive
breastfeeding is however recommended where replacement infant feeding is not acceptable, feasible, affordable, sustainable and safe

The use of prophylactic Amtiretroviral regimen to reduce the rate of
HIV transmission from mother to child has improved over the past ten years. Current WHO guidelines recommend a short-course regimen ideally consisting of AZT for the mother from week 28 of pregnancy, single dose nevirapine at the onset of labour, and AZT/3TC for 7 days after delivery. The infant should also receive a single dose of nevirapine at delivery, and AZT/3TC for 7 days. Mothers with CD4 cell counts below 350 should be considered for antiretroviral therapy. Despite the proven effectiveness of ARV to reduce rate of Mother to child transmission of HIV infection, mirage of logistic problems prevent the effective use of this innovation include the ineffectiveness of health systems. Less complex regimens are recommended where the health system cannot deliver this level of care, but even the delivery of single-dose nevirapine – the least effective regimen – has posed significant problems for health systems in sub-Saharan Africa. Detailed analysis of programme delivery in Zambia, for example, has shown that only one in three women diagnosed HIV-positive actually took nevirapine at delivery. But then only 30% of woment actually take an HIV test!

No recent analysis of potential technological improvements to PMTCT
programs has been carried out . Ongoing studies are investigating the efficacy of HAART (a ARV treatment regimen consisting of at least 3 drugs) and the safety and efficacy of tenofovir (a type of ARV).